Eli Lilly and Co (LLY) FinancialsLLYFinancialEli Lilly and Co

Eli Lilly and Company (LLY) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Diabetes-Mounjaro, accounting for 43.3% of total sales, equivalent to $9.94B. Other significant revenue streams include Diabetes-Zepbound and Oncology-Verzenio. Understanding this composition is critical for investors evaluating how LLY navigates market cycles within the Pharmaceuticals industry.

Evaluating the bottom line, Eli Lilly and Company maintains a gross margin of 85.78%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 54.22%, while the net margin is 30.88%. These profitability ratios, combined with a Return on Equity (ROE) of 102.44%, provide a clear picture of how effectively LLY converts its operational activities into shareholder value.

In the context of the broader market, LLY competes directly with industry leaders such as RDY and NVO. With a market capitalization of $1.11T, it holds a leading position in the sector. When comparing efficiency, LLY's gross margin of 85.78% stands against RDY's 46.52% and NVO's 78.21%. Such benchmarking helps identify whether Eli Lilly and Company is trading at a premium or discount relative to its financial performance.

Eli Lilly has shown impressive financial performance with a gross margin of 85.78% in Q2 2026 and a net income of $7.1 billion, reflecting strong profitability. The company has also demonstrated consistent revenue growth, with Q2 2026 revenue reaching $22.97 billion, up from $19.8 billion in Q1 2026.